Ist barley sh-oligopeptide-1 in der Schwangerschaft sicher?
No evidence of reproductive or developmental hazard was identified in authoritative sources. There is no harmonised CLP classification (ECHA Annex VI) for reproductive toxicity for 'barley sh-oligopeptide-1', no SCCS or CIR safety assessment flagging reproductive risk, and no peer‑reviewed reports of teratogenicity or endocrine disruption in PubMed. Peptides of this type are large biomolecules with low systemic absorption after topical application, so exposure is expected to be negligible for pregnancy.
Pregnancy-safe products containing barley sh-oligopeptide-1
Related ingredients
Frequently asked questions
- Ist barley sh-oligopeptide-1 in der Schwangerschaft sicher?
- No evidence of reproductive or developmental hazard was identified in authoritative sources. There is no harmonised CLP classification (ECHA Annex VI) for reproductive toxicity for 'barley sh-oligopeptide-1', no SCCS or CIR safety assessment flagging reproductive risk, and no peer‑reviewed reports of teratogenicity or endocrine disruption in PubMed. Peptides of this type are large biomolecules with low systemic absorption after topical application, so exposure is expected to be negligible for pregnancy.
- Ist barley sh-oligopeptide-1 während des Stillens sicher?
- No data indicate reproductive or lactation hazards. No harmonised classification or authoritative safety assessment (CIR/SCCS) indicates risk to breastfeeding; no peer‑reviewed evidence shows milk transfer or effects on lactation. Topical peptides are unlikely to achieve systemic levels sufficient to transfer into breast milk.
- Ist barley sh-oligopeptide-1 sicher für Babyhaut?
- No evidence of developmental or dermal toxicity in infants. Mechanistic concerns are not documented. However, infants (0–3 yr) have a higher skin permeability and higher surface‑area‑to‑weight ratio, so exposure potential is higher than in adults; adult dermal absorption for large oligopeptides is expected to be negligible, but given immature barrier function a conservative exposure score of 1 is applied. No infant‑specific adverse reports were found.
- Wie bewertet VeriMom barley sh-oligopeptide-1?
- VeriMom bewertet barley sh-oligopeptide-1 mit 100/100 (keine bekannten Risiken) basierend auf EU CosIng, ECHA-Klassifizierungen und PubMed-Studien.
- Was sind schwangerschaftssichere Alternativen zu barley sh-oligopeptide-1?
- Siehe unsere kuratierte Liste der schwangerschaftssicheren Alternativen zu barley sh-oligopeptide-1 basierend auf ähnlicher Funktion.
Prüfe jede Zutatenliste in 2 Sekunden
Lade VeriMom kostenlos — scanne jedes Produkt und sieh sofort die Schwangerschafts-Sicherheitsbewertung.
Medizinischer Haftungsausschluss
Diese Informationen dienen ausschließlich Bildungszwecken und stellen keine medizinische Beratung dar. Sicherheitsbewertungen basieren auf öffentlich zugänglichen Daten und spiegeln möglicherweise nicht alle Risiken wider. Konsultieren Sie immer Ihren Arzt, bevor Sie ein Produkt während der Schwangerschaft oder Stillzeit verwenden.


